Accession Number:

AD1000971

Title:

Wnt/beta-Catenin, Foxa2, and CXCR4 Axis Controls Prostate Cancer Progression

Descriptive Note:

Technical Report,01 Jul 2014,30 Jun 2015

Corporate Author:

Vanderbilt University Medical Center Nashville

Personal Author(s):

Report Date:

2015-07-01

Pagination or Media Count:

4.0

Abstract:

Wntbeta-Catenin signaling and associated target genes are implicated in the establishment of bone metastasisand in the development of castration resistant prostate cancer. Our previous studies have shown that Foxa2 is aWntbeta-catenin target gene in prostates. Our preliminary study suggests a WntFoxa2CXCR4 axis that isinvolved in PCa bone metastasis, and activation of this axis provides survival mechanisms for PCa cellsfollowing androgen deprivation. The hypothesis is that the Wntbeta-catenin activation of Foxa2 and CXCR4promotes progression to CRPCa and facilitates bone colonization by PCa cells, and that targeting this axis willprovide a novel treatment for PCa bone metastasis and relapse after androgen ablation.Last October 1st, I moved from Vanderbilt to LSU Health Sciences Center, Shreveport, LA. This award isundergoing an institutional transfer. Since funds have been tied up during the transition, I have not been ableto conduct any research related to this project since I moved to LSUHSC.

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE